Blueprint Medicines Corp
Blueprint Medicines Corp (BPMC): 12 pipeline candidates · ~33 mo cash runway · 15 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
33.0 months
D/E 2.49 · 3% dilution
Lead: Approved
12 candidates
N/A
N/A
A transparent, data-derived signal for Blueprint Medicines Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$134.1M
Quarterly Burn
$54.5M
Runway
33.0 mo
Revenue
$149.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| avapritinib | Phase 4 |
| ayvakit | Approved |
| blu-222 | Phase 1 |
| blu-263 | Phase 1 |
| blu-782 | Phase 2 |
| blu-808 | Phase 1 |
| blu-924 | Phase 1/Phase 2 |
| elenestinib | Phase 1 |
| gavreto | Approved |
| idrx-73 | Preclinical |
Showing 10 of 12 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in Blueprint Medicines Corp's pipeline?
Blueprint Medicines Corp (BPMC) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Blueprint Medicines Corp's lead drug candidate?
Blueprint Medicines Corp's most advanced tracked candidate is avapritinib (Phase 4) for Solid Tumor, Unspecified, Child; Indolent Systemic Mastocytosis; Mastocytosis, Systemic.
What is Blueprint Medicines Corp's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Blueprint Medicines Corp has approximately 33.0 months of cash runway.
Who is the CEO of Blueprint Medicines Corp?
Blueprint Medicines is the chief executive officer of Blueprint Medicines Corp (BPMC).
Get the full picture on Blueprint Medicines Corp
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.